ELDORADO
ELDORADO: a Randomized Phase II Trial of Elranatamab or Daratumumab in Combination With Lenalidomide, Bortezomib, and Dexamethasone (RVd Lite) in Newly Diagnosed, Transplant Ineligible/Deferred Multiple Myeloma
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 2
- Enrollment
- 160 patients (estimated)
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), Quadruplet Therapy, Randomization
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2225
- NCT Identifier
- NCT07247097
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.